Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
06:00am, Friday, 05'th Jan 2024
WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
07:00am, Tuesday, 02'nd Jan 2024
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
12:48pm, Friday, 08'th Dec 2023
Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.
Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with Rivian
05:49pm, Tuesday, 14'th Nov 2023
Soros Fund Management, the investment firm founded by billionaire George Soros, took new positions or bulked up on IPOs and a number of tech names during the third quarter.
Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases
02:27am, Sunday, 12'th Nov 2023
Kymera's KT-474 shows promise in Phase I for HS and AD, balancing clinical potential with financial challenges. Despite revenue decrease, Kymera's strong current ratio and ample cash reserves provide
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
01:10pm, Saturday, 04'th Nov 2023
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President and CEO Jare
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
07:00am, Wednesday, 01'st Nov 2023
WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
07:00am, Thursday, 26'th Oct 2023
WATERTOWN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:21am, Thursday, 19'th Oct 2023
Kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea
Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:19am, Wednesday, 18'th Oct 2023
The heavy selling pressure might have exhausted for Kymera Therapeutics, Inc. (KYMR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall
Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?
07:31am, Wednesday, 04'th Oct 2023
Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further
Why Shares of Kymera Therapeutics Jumped on Tuesday
04:48pm, Tuesday, 03'rd Oct 2023
Kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead therapy IRAK-4.
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
07:00am, Monday, 28'th Aug 2023
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
Kymera Therapeutics - Need More Developments Before Making This A Buy
04:21pm, Wednesday, 09'th Aug 2023
Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug Designation for KT-253, a potential treatment for
Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript
02:55am, Sunday, 06'th Aug 2023
Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Founder, President and CEO Jared Gollob - CMO Justin
